(Q30892564)

27 June 2017

0 references

Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data (English)

1 reference

27 June 2017

1 reference

1 reference

peginterferon alfa-2a

1 reference

1 reference

1 reference

1 reference

5

Stefan Zeuzem

1 reference

27 June 2017

Filippo Schepis

3

0 references

Antonio Craxì

object named as

Antonio Craxì

10

0 references

Patrick Marcellin

7

object named as

Patrick Marcellin

1 reference

27 June 2017

8

Luis Balart

1 reference

27 June 2017

Calogero Cammà

1

1 reference

27 June 2017

Danilo Di Bona

2

1 reference

27 June 2017

E Jenny Heathcote

4

1 reference

27 June 2017

Paul J Pockros

6

1 reference

27 June 2017

Alfredo Alberti

9

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

27 June 2017

1 reference

27 June 2017

volume

39

1 reference

27 June 2017

issue

2

1 reference

27 June 2017

page(s)

333-342

1 reference

Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C.

27 June 2017

cites work

1 reference

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

Sponsorship, Authorship, and Accountability

21 January 2018

1 reference

Meta-analysis in clinical trials

21 January 2018

1 reference

Definition of response to antiviral therapy in chronic hepatitis C.

21 January 2018

1 reference

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

21 January 2018

1 reference

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

Historical features are poor predictors of liver fibrosis in Canadian patients with chronic hepatitis C.

21 January 2018

1 reference

The long-term pathological evolution of chronic hepatitis C.

21 January 2018

1 reference

7 January 2021

The pathology of hepatitis C

1 reference

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

7 January 2021

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

7 January 2021

The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis

1 reference

7 January 2021

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

1 reference

7 January 2021

Methods for assessing whether change depends on initial value

1 reference

7 January 2021

Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis

1 reference

7 January 2021

Liver fibrosis in overweight patients

1 reference

7 January 2021

Body composition and hepatic steatosis as precursors for fibrotic liver disease

1 reference

7 January 2021

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.20073

1 reference

27 June 2017

1 reference